Table 1.
Patient Characteristics
| Myeloid sarcoma N=23 (%) |
Acute myeloid leukemia N=1720 (%) |
|
|---|---|---|
| Age | ||
| Median | 57 | 60 |
| Range | 7-81 | 14-89 |
| Zubrod PS | ||
| 0 | 8 (35) | 158 (9) |
| 1 | 13 (57) | 1006 (58) |
| 2 | 1 (4) | 383 (22) |
| 3 | 1 (4) | 112 (7) |
| 4 | 0 (0) | 61 (4) |
| Cytogenetics | ||
| Inv 16 or t(8;21) | 2 (9) | 138 (8) |
| Normal | 11 (48) | 640 (37) |
| +8 | 5 (22)* | 127 (7) |
| -5, -7 | 1 (4) | 372 (22) |
| Abnormal 11 q or other ** | 3 (11) | 358 (21) |
| Insufficient | 0 | 76 (4) |
| Not done | 0 | 9 (0.005) |
| AHD | 3 (13) | 688 (40) |
| WBC count | ||
| Median | 6.7 | 10.1 |
| Range | 1.3 - 70.6 | 0.2 - 394 |
| Hemoglobin | ||
| Median | 13.5 | 8.0 |
| Range | 4.8 - 16.1 | 2.1 - 15.0 |
| Platelets | ||
| Median | 246 | 48 |
| Range | 110 - 534 | 2 - 2292 |
| Post-remission therapy | ||
| Idarubicin+AraC, % | 40 | 44 |
| Low-dose AraC, % | 8 | 0 |
| None, % | 24 | 0 |
| Other, % | 8 | 10 |
| Fludarabine+AraC, % | 8 | 0 |
| Topotecan+AraC +/- Cyclophosphamide, % | 8 | 14 |
| Stem cell transplantation, % | 0 | 1 |
| Therapy at 1st relapse | ||
| High-dose AraC, % | 25 | 7 |
| Fludarabine+AraC+Topotecan, % | 25 | 0 |
| Fludarabine+AraC+Idarubicin, % | 0 | 20 |
| Idarubicin+AraC, % | 25 | 17 |
| Topotecan+AraC+/- Cyclophosphamide, % | 0 | 12 |
| Decitabine + 5-azacytidine, % | 0 | 3 |
| Stem cell transplantation, % | 0 | 9 |
| Other, % | 25 | 27 |
| Unknown, % | 0 | 5 |
AHD = Antecedent hematologic disorder; PS = performance status; WBC = white blood cells
*
One additional patient had 8q deletion.
**
These chromosomal abnormalities were del12 (1 patient) and dup1 (1 patient).